Adoptive transfer of ex vivo expanded tumor-specific T cells is a promising therapeutic modality for promoting or augmenting antitumor immunity. Several groups, including ours, are developing antigen receptor gene transfer strategies as a means of generating effector cells for adoptive therapy. Chimeric antigen receptors (CARs) have been described that use single-chain antibodies or cytokine ligands as tumor targeting domains. Here, we describe the capacity of a tumor-binding peptide identified by phage display combinatorial library screening to serve as a CAR targeting domain. A phage library-selected high-affinity 12-mer peptide (Bpep) specific for alpha(v) beta(6) integrin (avb6) was chosen for these studies. Primary human T cells were genetically modified to express the Bpep-CAR consisting of an avb6-specific peptide and human IgG4 hinge-Fc extracellular domain fused to the cytoplasmic tail of CD3-z. T cell expression of the Bpep-CAR was assessed by Western blot analysis, and trafficking of the Bpep-CAR to the cell surface was demonstrated by flow cytometry. Functionally, Bpep-CAR redirected cytotoxic T lymphocytes specifically kill integrin avb6 þ ovarian tumor targets, and are activated for interferon gamma secretion. Our data suggest that large new repertoires of tumor-specific T cell antigen receptor transgenes might be available through merging combinatorial peptide libraries with CAR construct design.
Introduction
The therapeutic utility of adoptive immunotherapy for the treatment of viral and malignant disease continues to grow, with ongoing intensive laboratory research, as well as, clinical trials focused on enhancing the potency and consistency of the therapeutic effect. 1 Genetic modification of T lymphocytes, via electroporation or the use of viral vectors, represents a versatile platform for manipulating the immunobiology of these effector cells and/or enhancing the safety of cell transfer. 2 One focus of T cell gene transfer applications is the redirection of T cell antigen specificity through the expression of chimeric antigen receptors (CAR). [2] [3] [4] [5] With these technologies in hand, the task becomes the identification of tumor targets that are specific, preferably common, and that are amenable to specific engagement through CAR targeting domains. To date, these targeting domains have been predominantly single-chain Fvs or ligands for receptors on the tumor cell surface.
The integrin avb6 is expressed by many fetal epithelial tissues, but expression is essentially absent from normal adult epithelium, except at the leading edge of healing wounds during re-epithelialization. 6 Expression of avb6 has also been demonstrated in ovarian, pancreatic, colonic and oral squamous cell carcinomas. 6, 7 The staining intensity of avb6 seems to correlate with the grade of ovarian cancer, and can distinguish benign from malignant neoplasms. 7 Moreover, avb6 integrin may be integrally linked to the malignant phenotype of tumors as this integrin promotes tumor invasion and metastasis by regulating collagenase production. 8 Given that avb6 integrin is selectively expressed on carcinoma cells and linked to high-risk metastatic disease, it is an attractive target for immunotherapy.
Phage display is a powerful tool to identify small peptide sequences that mimic ligands, and has been successfully employed in identifying high-affinity peptide ligands for avb6 integrin. 9 Goodman and co-workers have identified several peptides that bind specifically to avb6 and not other integrins. Fibronectin is the ligand for avb6, and this interaction is strongly inhibited by the peptide RTDLDSLRTYTL. The half-maximal inhibitory concentration of the peptide-avb6 interaction is 20 nM, and is specific to this integrin, as this peptide does not affect fibronectin binding to integrins avb3, avb5 or aIIbb3. 9 Here, we describe a peptide chimeric T cell receptor based on this 12 amino acid (aa) peptide targeting moiety, and demonstrate its capacity to redirect the effector function of T cells to avb6 integrin-expressing ovarian carcinoma cells.
Materials and methods

Plasmid DNA
The chimeric peptide-specific T cell receptor genes were constructed by splice-overlap polymerase chain reaction. The DNA for the anti-avb6 peptide was designed based on the sequence described by Kraft et al. 9 of a 12-aa peptide ligand (RTDLDSLRTYTL) for avb6. The remainder of the construct has been previously described by Jensen et al. 3 In brief, the final chimeric construct consists of a Kozak consensus ribosome binding sequence; granulocyte macrophage colony-stimulating factor (GM-CSF) receptor alpha leader sequence; avb6-specific binding peptide Bpep; triple glycine linker; hinge Fc; CD4 transmembrane region; and the cytoplasmic domain of the CD3-z chain. Flanking XbaI and NotI restriction sites were included to allow cloning of the DNA sequence into the mammalian expression vector pMG under the control of the EF1 promoter (Stratagene, La Jolla, CA). This vector contains a hygromycin resistance gene for cell selection. Correct assembly was confirmed by DNA sequence analysis. The Bpep-CAR plasmid was propagated in Escherichia coli (DH5a) and purified using Qiagen's Endo-Free Maxi prep kit, as per the manufacturer's instructions. The plasmid was linearized at a unique pacI site by overnight incubation of 0.5 U of enzyme per microgram of DNA. Complete digestion was confirmed with gel electrophoresis. The plasmid DNA was precipitated with a 1:10 volume of 3 M sodium acetate and 2.5 volume of ethanol (EtOH), washed in 70% EtOH and resuspended in sterile distilled H 2 O. Linearized Bpep-CAR DNA was stored at À201C until used for electroporation. Low passage primary human ovarian cancer cell lines (RSN001 and RSN002) were established in the laboratory according to previously published methods by Alama et al. 10 Ascites was collected from women with ovarian cancer who were undergoing an exploratory laparotomy. The ascites was centrifuged at 1200 r.p.m. for 10 min. The supernatant was collected and stored at 41C. If the specimen had a significant number of red blood cells, they were separated by density-gradient centrifugation with Ficoll-Paque Plus. The cells were washed twice with phosphate-buffered saline (PBS) and seeded at a density of 5-10 Â 10 6 cells per T-75 flask in RPMI-1640 media containing 10% FCS, 100 U/ml penicillin/streptomycin (Cambrex), 2 mM L-glutamine, 25 mM HEPES and 10% volume of that patient's ascites. The ascites was added to the media for the first five passages. This study was approved by the City of Hope Institutional Review Board, and all patients signed informed consent.
Cell lines
T cells were maintained in tissue culture using 14-day stimulation cycles. On day 0 of each cycle, 10 5 T cells were mixed with 5 Â 10 7 peripheral blood mononuclear cells (PBMCs) irradiated at 3500 cGy, 10 Â 10 7 lymphoblastoid cells (LCLs) irradiated at 8000 cGy and 30 ng/ml OKT3 (Ortho Biotech, Bridgewater, NJ) in RPMI-1640 media supplemented with 2 mM L-glutamine, 25 mM HEPES and 10% FCS. Starting on day 1 of each stimulation cycle, recombinant human interleukin 2 (rhIL-2) (Chiron, Emeryville, CA) at either 25 U/ml (T cell bulk culture) or 50 U/ml (T cell clones) was added every 48 h. Media was exchanged and cells split as needed.
For genetic modification of primary human T cells by electroporation, PBMCs were isolated by density-gradient centrifugation over Ficoll-Paque Plus. OKT3-activated T cells were electroporated on day 1, with 1.25 mg DNA per 10 6 cells. Cells were electroporated once at 250 V for 40 ms, then stimulated in phenol red-free media with PBMCs, LCLs and OKT3 as described above. On day 6 after electroporation, and day 5 of each stimulation cycle, Hygromycin B (InvivoGen, San Diego, CA, USA) at 0.2 mg/ml was added to select for genetically modified T cells. T cells were cloned on day 0 of a stimulation cycle in 96-well plates by limiting dilution using a mixture of irradiated PBMC and LCL with OKT3 at 30 ng/ml and rhIL-2 at 50 U/ml. Five days after plating, Hygromycin B at 0.2 mg/ml was added. The clones were screened by flow cytometry for Fc expression on day 18 of the cycle. Clones that were positive and demonstrated good growth were expanded.
Western blot
Whole-cell lysates of transfected T cells were prepared as follows: 10 6 cells were washed with PBS and resuspended in 50 ml radioimmuno-precipitation assay buffer (1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate) with protease inhibitors on ice for 1 h. Cell lysates were centrifuged at 41C for 20 min at 15 000 r.p.m. Thirty microliters of supernatant was added to 60 ml of Laemmli-loading buffer. The protein sample was boiled at 1001C for 3 min, separated on a 15% SDS-polyacrylamide gel electrophoresis gel and then transferred onto a nitrocellulose membrane. The membrane was blocked for 1 h with 4% milk protein in T-TBS (Tris-buffered saline with 0.1% Tween-20), incubated with a 1:500 dilution of mouse anti-human CD3 zeta antibody (BD Biosciences, Franklin Lakes, NJ, USA) for 2 h, washed with T-TBS and incubated with a goat anti-mouse alkaline phosphatase secondary antibody (Bio-Rad, Hercules, CA, USA) for 30 min. Protein was detected with ImmunStar Enhancer and Substrate solution (Bio-Rad), as per the manufacturer's instructions. Plates were incubated at 371C for 4 h. The supernatant (100 ml) was collected, and released 51 Cr was measured using a gamma counter (Cobra II, PerkinElmer, Shelton, CT, USA). The percent specific 51 Cr lysis was calculated as (test release)À(spontaneous release)/(maximum release) À(spontaneous release) Â 100. 
Flow cytometry
In vitro stimulation T cell bulk lines or clones on days 12-14 of the stimulation cycle were co-cultured with tumor targets at a 10:1 T cell to target ratio. The assay was performed by incubating 5 Â 10 4 targets with 5 Â 10 5 T cells per well for 48 h in media without IL-2. For the in vitro stimulation assay (IVS) with peptide blocking, the 12 aa B-peptide (RTDLDSLRTYTL) that is the ligand for avb6 or a nonspecific K-peptide (ATWLPPR) was added to the OVCAR-3 cells 2 h before adding the T cells. After 48 h, the culture supernatant was collected, centrifuged and the cell-free supernatant collected and stored at À201C until it was analyzed. Interferon gamma (IFN-g) production was measured with a cytometric bead array (CBA) kit according to the manufacturer's instructions (BD Biosciences Human Th1/Th2 Cytokine Kit). Samples were acquired and analyzed using the FACSCalibur and BD CBA analysis software.
Results
Design of an avb6-specific peptide-CAR in primary human T cells
The avb6-specific peptide-CAR consists of the 12 aa peptide RTDLDSLRTYTL followed by a triple glycine linker, an IgG4 hinge region, the CD4 transmembrane domain and the cytoplasmic signaling domain of CD3 zeta (CD3-z) (Figure 1a ). This CAR was given the designation of 'Bpep.' The Bpep immuno-receptor was fused to the GM-CSF receptor alpha chain leader sequence, and expressed under the control of the constitutive EF1 promoter from the pMG vector (Figure 1b) . A three-dimensional schematic of the mature Bpep receptor as a type I transmembrane chimeric protein is depicted in Figure 1c .
The Bpep-CAR is expressed by T cells as a cell-surface transmembrane protein
The Bpep-CAR was introduced into OKT3-activated PBMCs by electroporation, and in the presence of cytocidal concentrations of hygromycin, a population of cytotoxic T lymphocyte (CTL) transfectants were expanded using repetitive cycles of stimulation with OKT3, irradiated feeders and low-dose IL-2. Drug selected T cells stably express the Bpep-CAR as demonstrated by Western blot analysis of reduced whole-cell lysates probed with a monoclonal antibody specific for the CD3-z chain (Figure 2a) . The Bpep-CAR (44 kDa) in the expanded bulk and clone lines (lanes 2 and 3) is expressed at equivalent or greater levels than a CD19-specific scFvFc:zeta CAR (91 kDa) expressed by CTL clone E8 (lane 4). 11 The CD19R-chimeric immuno-receptor, previously developed in our laboratory, 11 consists of a CD19- sion above the isotype control (Figure 2b) , confirming that the Bpep-CAR traffics to the cell surface of the genetically modified CTL.
The Bpep-CAR þ lymphocytes cloned from the bulk culture were characterized by flow cytometry for lymphocyte, monocyte and natural killer cell-surface antigens. The Bpep-CAR þ CTLs display the effector T cell phenotype (T cell receptor (TCR)
À ; data not shown), and this particular bulk Tcell line was CD3 þ CD4 À CD8 þ (Figure 2c ).
Bpep-CAR þ T cells exhibit redirected recognition and lysis of avb6 integrin þ ovarian carcinoma targets Cell-surface expression of avb6 integrin was evaluated for the ovarian cancer cell line OVCAR-3 and low passage primary ovarian tumor lines RSN001 and RSN002. Cell lines were incubated with an anti-human avb6 antibody followed by FITC-conjugated anti-IgG. Flow cytometric analysis demonstrated that the ovarian cancer lines all express the integrin avb6, with the RSN002 line having the highest expression (Figure 3) . By comparison, the Daudi and SUP-B15 lymphoma cell lines do not express significant levels of the avb6 integrin (Figure 3 and data not shown). These observations corroborate previous studies demonstrating that expression of integrin avb6 is associated with epithelial ovarian cancer. 7 We next evaluated the ability of Bpep-CAR þ CTL to specifically kill avb6 þ cancer cell targets. The bulk line and CTL clones A9 and A11 were co-cultured with OVCAR-3, RSN001 and RSN002 in a chromium release assay (CRA) at E:T ratios of 50:1, 25:1, 5:1 and 1:1 in triplicate. The Bpep-CAR þ CTL bulk line and CTL clones displayed cytolytic activity against the avb6 þ tumors (Figure 4a) , with up to 72% lysis of the RSN002 line at the 50:1 E:T ratio. To demonstrate antigen-specific cytolytic activity, the Bpep-CAR þ CTL clone A9 was co-cultured in a CRA with either avb6 þ CD19 À OVCAR-3 or avb6 À CD19 þ SUP-B15 targets. As shown in Figure 4b , the avb6 þ OVCAR cells were lysed by the Bpep-CAR þ clone A9, but the avb6 À SUP-B15 targets were not lysed. By comparison, the CD19-specific CTL clone E8 expressing an anti-CD19 scFvSc:zeta CAR lyses CD19 þ SUP-B15 targets, but not the CD19 À OVCAR-3 cells. Taken together, these data demonstrate that the Bpep-CAR þ CTL display antigen-specific cytolytic activity with little or no crossreactivity.
The Bpep-CAR þ activates T cells for cytokine production upon tumor binding To determine whether the Bpep-CAR provides an activation signal for cytokine production upon engagement of avb6 þ targets, an IVS was performed with the Bpep-CAR þ T cell clone A9, and OVCAR-3 or Daudi targets at a 10:1 E:T ratio. Bpep-CAR þ T cell responders produce a 10-fold higher level of IFN-g upon co-culture with OVCAR-3, as compared to Daudi stimulators (Figure 5a ). Cytokine production was dependent on Bpep-CAR þ engagement of avb6 integrin, as it was blocked by the addition of the soluble 12-mer avb6-binding peptide in a dose-dependent manner (Figure 5b) . By contrast, addition of an irrelevant peptide (ATWLPPR) to co-cultures had no consistent inhibitory effect on cytokine production.
Discussion
In this work, we evaluated the capacity of a small 12-mer peptide selected from a phage display library for highaffinity binding to avb6 integrin to function as a targeting domain in a chimeric T cell antigen receptor. We found that such a minimal targeting domain can be incorporated into the CAR protein and that this Bpep-CAR is expressed and transported to the surface of T cells where it is capable of binding its tumor cell-surface target and triggering T cell cytolysis and cytokine effector mechanisms. These proof-of-concept data represent a new platform for high-throughput combinatorial library screening leading to cellular immunotherapy applications for cancer.
Whereas scFv and receptor ligand targeting domains represent a limited repertoire of specificities, 12, 13 combinatorial peptide libraries can generate a vast number of targeting peptides. Additionally, because scFvs typically are generated in a retroactive manner from hybridomas, the repertoire of epitopes is constrained to those that differ between the B-cell donor (usually mouse) and human. Chemically or genetically constructed peptide libraries are therefore much more opened-ended with respect to what can be targeted, with selection methodologies being amenable to identifying binding peptides for molecularly defined targets as well as tumor-binding properties when the target is not specified. Further, affinity modulation of peptides is typically a straightforward process, whereas it can be more challenging for scFvs and cytokines. 13 A conceptually interesting extension of this work will be to study the effect of valency on the immunobiology of these receptors. The small size of the peptide targeting domain makes it amenable to presentation as a string of several copies of the same peptide with interspersed flexible linkers. Additionally, we propose that it might be possible to engineer multiple specificities by including different peptide targeting domains into a single chimera, an approach that addresses the important translational issue of antigenic variability and escape in tumor immunotherapy. By having multi-specific chimeras that diversify recognition by T cells to combinations of tumor, tumor stroma and angiogenic endothelium, therapeutically additive or synergistic potency might be anticipated.
Our current work describes a Bpep-CAR specific for avb6 integrin frequently expressed by carcinomas, in particular, ovarian carcinoma. We are developing clinical applications for this patient population that will utilize loco-regional adoptive transfer into the peritoneum. Whereas the current Bpep-CAR construct consists of the CD3-z cytoplasmic signaling domain, we are currently evaluating compound signaling domains incorporating CD28 and 4-1BB modules capable of supporting the survival and recycling of T cell transfectants. These second generation constructs are now entering initial first-in-human clinical trials. Together with recent insights into the benefit of lymphodepletion for supporting homeostatic proliferation of transferred T cells and evolving appreciation for recipient modification through immunologic checkpoint blockade, the interplay of cellular immunotherapy and gene transfer will be the subject of significant clinical exploration over the next decade. 
